Analysed CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) News Sources
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
08-04-2026
yahoo.com
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
06-04-2026
yahoo.com
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
02-04-2026
yahoo.com
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
30-03-2026
yahoo.com
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
18-03-2026
yahoo.com
What is the current price of CURANEX PHARMACEUTICALS INC (CURX:NASDAQ)?
The current price of CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) is $0.4641.
CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) since the previous trading day is $-0.0061.
CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) since the previous trading day is -1.2973%.
What is the most recent average sentiment score for CURANEX PHARMACEUTICALS INC (CURX:NASDAQ)?
The most recent average sentiment score for CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for CURANEX PHARMACEUTICALS INC (CURX:NASDAQ)?
The most recent sentiment for CURANEX PHARMACEUTICALS INC (CURX:NASDAQ) is .
SEC-8K** Filing Available For CURANEX PHARMACEUTICALS INC (CURX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.